Literature DB >> 8840976

Immortalization and transformation are associated with specific alterations in choline metabolism.

K K Bhakoo1, S R Williams, C L Florian, H Land, M D Noble.   

Abstract

Analysis of transformed, immortalized, and primary rat Schwann cells by high-resolution proton nuclear magnetic resonance spectroscopy reveals that immortalization of Schwann cells (by SV40 large T antigen) induced a decrease in sn-glycero-3-phosphocholine (GPCho), whereas H-ras alone, which is known to cause growth arrest in these cells, induced a marked increase in GPCho and a decrease in phosphocholine (PCho). An increase of PCho was found only in cells fully transformed by both oncogenes together. Moreover, we examined 11 human tumor cell lines, all of which expressed a PCho:GPCho ratio similar to that of fully transformed rat Schwann cells. Importantly, neither the absolute levels of PCho nor the ratio of PCho:GPCho were correlated with the rate of cell division across a range of normal (primary cultures) and transformed cells. Thus, raised PCho:GPCho ratios may serve as an indicator of multiple oncogenic lesions and malignancy in noninvasive tumor investigations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Authors:  Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

2.  Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells.

Authors:  Tariq Shah; Flonne Wildes; Marie-France Penet; Paul T Winnard; Kristine Glunde; Dmitri Artemov; Ellen Ackerstaff; Barjor Gimi; Samata Kakkad; Venu Raman; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2010-07       Impact factor: 4.044

3.  Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.

Authors:  Sean P Arlauckas; Anatoliy V Popov; Edward J Delikatny
Journal:  Mol Cancer Ther       Date:  2014-07-15       Impact factor: 6.261

4.  In vivo detection of phospholipase C by enzyme-activated near-infrared probes.

Authors:  Theresa M Mawn; Anatoliy V Popov; Nancy J Beardsley; Klara Stefflova; Matthew Milkevitch; Gang Zheng; E James Delikatny
Journal:  Bioconjug Chem       Date:  2011-11-29       Impact factor: 4.774

5.  Variation of post-treatment H-MRSI choline intensity in pediatric gliomas.

Authors:  J A Lazareff; R K Gupta; J Alger
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 6.  PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature.

Authors:  Koen Mertens; Dominique Slaets; Bieke Lambert; Marjan Acou; Filip De Vos; Ingeborg Goethals
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-11       Impact factor: 9.236

7.  Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis.

Authors:  Gengshu Wu; Chieko Aoyama; Stephen G Young; Dennis E Vance
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

8.  Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.

Authors:  Reinhold Nafe; Sebastian Herminghaus; Peter Raab; Sabine Wagner; Ulrich Pilatus; Berthold Schneider; Wolfgang Schlote; Friedhelm Zanella; Heinrich Lanfermann
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

9.  Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (1H MRS).

Authors:  M Lindskog; P Kogner; F Ponthan; P Schweinhardt; B Sandstedt; T Heiden; G Helms; C Spenger
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

10.  Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells.

Authors:  Boon Tin Chua; David Gallego-Ortega; Ana Ramirez de Molina; Axel Ullrich; Juan Carlos Lacal; Julian Downward
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.